WALTHAM, Mass., Feb. 7, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today that the Company will hold an Investor and Analyst Briefing and webcast for analysts and institutional investors on Monday, February 13, 2012 from 12:00 – 2:30 p.m. Eastern Time. Eric Bouvier, PhD, President and CEO of BG Medicine, will host the event along with other key members of senior management. The presentation will include a discussion on the medical need, validation study results and market potential for AMI PredictTM, the Company’s blood test to identify patients at risk of near-term heart attack and stroke. In addition, the Company will also discuss its launch progress, label extension plans and distribution partner updates for its marketed BGM Galectin-3TM test for use in patients with heart failure. Presentations will be available to the public through a webcast accessible by visiting http://investor.bg-medicine.com/events.cfm or the “Investors” section of the Company’s website at www.bg-medicine.com. Replays will be available for 30 days after the presentation.
